A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology
暂无分享,去创建一个
[1] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[2] A. Rong,et al. Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials , 2013, Clinical Cancer Research.
[3] C. Twelves,et al. A Dynamic Model of Hand‐and‐Foot Syndrome in Patients Receiving Capecitabine , 2009, Clinical pharmacology and therapeutics.
[4] B P Booth,et al. Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development , 2009, Clinical pharmacology and therapeutics.
[5] Yu‐Nien Sun,et al. Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer , 2010, Cancer Chemotherapy and Pharmacology.
[6] Jan Fagerberg,et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Lena E Friberg,et al. Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response , 2013, British journal of clinical pharmacology.
[8] G. Demetri,et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.
[9] J. Crowley,et al. Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors , 2013, Clinical Cancer Research.
[10] L E Friberg,et al. A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis , 2014, CPT: pharmacometrics & systems pharmacology.
[11] M. Buyse,et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Nenad Sarapa,et al. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] B. Ribba,et al. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor. , 2010, Urology.
[14] France Mentré,et al. Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches , 2015, The AAPS Journal.
[15] D R Stanski,et al. Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited. , 1990, Anesthesiology.
[16] Michael L Maitland,et al. RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point. , 2012, Cancer research.
[17] Johan Pallud,et al. A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy , 2012, Clinical Cancer Research.
[18] D. Ankerst,et al. Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials , 2012, Clinical Cancer Research.
[19] L E Friberg,et al. PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST , 2013, CPT: pharmacometrics & systems pharmacology.
[20] M. Karlsson,et al. PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST , 2013, CPT: pharmacometrics & systems pharmacology.
[21] R. Bruno,et al. On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies , 2009, Clinical pharmacology and therapeutics.
[22] J. Cuzick,et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer , 2008, British Journal of Cancer.
[23] B. Agoram,et al. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy , 2006, The AAPS Journal.
[24] L. Sheiner,et al. Modelling of individual pharmacokinetics for computer-aided drug dosage. , 1972, Computers and biomedical research, an international journal.
[25] Mark J Ratain,et al. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data , 1980, Journal of Pharmacokinetics and Biopharmaceutics.
[27] T. Fojo,et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. , 2011, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial , 2012, BMC Cancer.
[29] N. Holford. A Time to Event Tutorial for Pharmacometricians , 2013, CPT: pharmacometrics & systems pharmacology.
[30] A. Iliadis,et al. Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer , 2011, Cancer Chemotherapy and Pharmacology.
[31] F J Lewis,et al. Continuous patient monitoring with a small digital computer. , 1972, Computers and biomedical research, an international journal.
[32] Mats O Karlsson,et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Peter L. Bonate,et al. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma , 2013, Cancer Chemotherapy and Pharmacology.
[34] J. Pérez-Ruixo,et al. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment , 2008, Cancer Chemotherapy and Pharmacology.
[35] A. Ruffion,et al. Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy , 2009, The Prostate.
[36] Mats O. Karlsson,et al. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080 , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[37] B. Ribba,et al. A Population Pharmacodynamic Model for Lactate Dehydrogenase and Neuron Specific Enolase to Predict Tumor Progression in Small Cell Lung Cancer Patients , 2014, The AAPS Journal.
[38] J. Verweij,et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea , 2002, Clinical pharmacology and therapeutics.
[39] Dominique Barbolosi,et al. Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy-Toxicity Mathematical Model , 2000, Comput. Biomed. Res..
[40] Nicholas H G Holford,et al. A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non–Small Cell Lung Cancer Patients , 2008, Clinical Cancer Research.
[41] M. Maitland,et al. Estimation of renal cell carcinoma treatment effects from disease progression modeling , 2012, Clinical pharmacology and therapeutics.